FDA says no to AZ’s Fasenra for nasal polyp indication
Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
KEYPOINTS: Spirofy is India’s first pneumotach-based portable wireless Spirometer for the diagnosis of COPD and asthma. The company intends with this launch…
Abstract: The National Institute for Health and Care Excellence (NICE) has issued an Appraisal Consultation Document (ACD) for AstraZeneca’s Forxiga (Dapagliflozin) within…